Sensei Biotherapeutics, Inc. $FTH Stock Position Raised by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 178.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the quarter. Renaissance Technologies LLC owned 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent filing with the Securities & Exchange Commission.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson acquired 9,391 shares of the stock in a transaction dated Wednesday, June 24th. The shares were bought at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This trade represents a 53.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders acquired 49,494 shares of company stock valued at $1,188,822 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on FTH. Leerink Partners initiated coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. Oppenheimer began coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price on the stock. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a report on Thursday, May 28th. Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target for the company. Finally, Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $54.90.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock opened at $32.34 on Friday. Sensei Biotherapeutics, Inc. has a 52-week low of $7.21 and a 52-week high of $37.90. The company has a market cap of $835.67 million, a price-to-earnings ratio of -0.23 and a beta of -0.25. The firm has a fifty day simple moving average of $26.65.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter. As a group, sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Sensei Biotherapeutics Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.